Corporate Update
2022 Achievements & 2023 Plans
February 2, 2023
Fredrik Brag
Chief Executive Officer and Founder
2023 & Beyond: The Big Take Off
Growing penetration of imaging AI in
patient care
- RSNA 2022 key take away: Imaging AI is now a reality and will have a major impact on disease diagnostics
- Breakthrough: 3 companies obtained a reimbursement of $650-$1,000 for imaging AI diagnostic solutions in 2022
- Major study at RSNA showed 92% of LC patients alive after 15 years when diagnosed in Stage 1. Cancer is curable
- People eligible for LCS in the US has doubled from 7.5m to 15m
- European Union's initiative to accelerate implementation of LCS national programs, 22m people potentially eligible for LCS
- The TAM is > $30bn in the US & EU and could double with Asia
- iBiopsy® LCS SaMD has the highest performance
Growing penetration of imaging AI with
the pharma
- Major interest for imaging AI by all life sciences stakeholders
- Pharma operating a stage shift to treat early-stage disease to increase chance of success
- Imaging AI will revolutionize drug development:
- Cancer detection & characterization
- Molecular status prediction
- Response predictions / Companion diagnostics
- Median Imaging lab can provide state of the art solutions
- Median core iCRO business expected to grow significantly
Median intends to sign a strategic | Median intends to sign strategic |
commercial partnership for the 2024 | |
partnerships with big pharma | |
launch of LCS SaMD in the US | |
2 www.mediantechnologies.com | Company Webcast | February 2, 2023
2022 Achievements
3 www.mediantechnologies.com | Company Webcast | February 2, 2023
2022 Key Performance
As of December 31, 2022
2022 revenue at €23.8M
- An increase of 16% compared to 2021 revenue (€20.5M).
Order backlog at €60.8M
Cash and cash equivalents at €21.5M
4 www.mediantechnologies.com | Company Webcast | February 2, 2023
25
20
15
10
5
0
Full Year Revenue (m€)
23.8
20.5
13.5
9
Full Year 2019 | Full Year 2020 | Full Year 2021 | Full Year 2022 |
Nota: company revenue comes from the iCRO BU solely, as iBiopsy® doesn't generate revenue at this stage (R&D)
Release date: January 19, 2023
2022 Macro Geopolitical and Economic Impacts
Small and mid-caps hit by turmoil on
financial markets
- Small & mid-caps hit by low liquidity
- Median liquidity: Q4 2022 day-average:
€141k vs Q1 2022 day-average: €630k - Negative asset flows: technology, healthcare and biotechnology equity
- The need for liquidity by certain funds have had a major impact on the share price
5 www.mediantechnologies.com | Company Webcast | February 2, 2023
China lockdown
- The Chinese lockdown has had a major impact on our Chinese clients during the bigger part of 2022
- The situation is expected to come back to normal quite quickly now that the country has opened up again
Inflation & general economic impact
- Some of our mid size biotechs clients have had funding issues which have slowed down some expected trials. The larger biotechs are now getting funded
- Perspectum raised $36m at $300m valuation
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Median Technologies SA published this content on 03 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 February 2023 11:07:09 UTC.